News on Wellness

Pfizer Shows New Hope From Breast Cancer Clinical Trial Medication


Pharmaceutical giant Pfizer has reported an experimental drug for treating breast cancer in advanced stage has shown promising results. In a trial of 165 patients it prevented the disease from worsening for 20.2 months where as the currently available medications do so only for 10.2 months.
The world’s second largest drugmaker says the so-called palbociclib drug targets specific protein to block the cancer tumors.

University of Michigan business professor Erik Gordon said the outcome of the trial was not as positive as some of the initial trials on earlier few tests, but there is of course some good hope surrounding.

Prof. Gordon was not affiliated with the latest trial. He studies the biomedical industry.

Breast cancer is the most common cancer among women. The latest trial of Pfizer was closely watched by Wall Street analysts.

Prof. Gordon added further that the investors expected more from the trial and hence some of them are disappointed as in earlier results the duration was 18 additional months from worsening.

The new results of the trial was presented during the annual meeting of the American Association of Cancer Research in San Diego by associate professor of medicine in UCLA, Dr. Richard S. Finn.

The US Food and Drug Administration (FDA) though sometimes accelerates approval for some promising drugs, but the palbociclib still needs to undergo broader testing with more patients.

Few other drugmaers such as Novartis and Eli Lilly also have similar medications and are undergoing clinical trials.

Leave a Reply

Your email address will not be published. Required fields are marked *